Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: An association with glucose-lowering effects

Endocrine Journal

Volumn 64, Issue 3, 2017, Pages 363-367

  Takase, Takahiro ^a   Nakamura, Akinobu ^a   Miyoshi, Hideaki ^a   Yamamoto, Chiho ^a   Atsumi, Tatsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fatty liver; Ipragliflozin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; IPRAGLIFLOZIN; ANTIDIABETIC AGENT; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPOTROPIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; AGED; BODY COMPOSITION; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIGESTIVE TRACT PARAMETERS; FAT MASS; FATTY LIVER; FATTY LIVER INDEX; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRAPERITONEAL FAT; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SUBCUTANEOUS FAT; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERGLYCEMIA; JAPAN; LIVER; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADIPOSITY; ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; LIPOTROPIC AGENTS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 85016590472     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ16-0295     Document Type: Note

References (20)

1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, et al. (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-131.
2. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, et al. (2012) Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 47: 586-595.
3. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, et al. (2015) Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care 38: 1347-1355.
4. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, et al. (2012) Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 107: 253-261.
5. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, et al. (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59: 969-974.
6. Kashiwagi A, Kazuta K, Yoshida S, Nagase I (2014) Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 5: 382-391.
7. Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, et al. (2015) A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 17: 152-160.
8. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, et al. (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715: 246-255.
9. Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, et al. (2016) The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 11: e0146337.
10. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, et al. (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 11: e0151511.
11. Kashiwagi A, Kazuta K, Takinami Y, Yoshida S, Utsuno A, et al. (2015) Ipragliflozin improves glycemic control in Japanese patients with type 2 daibetes mellitus: the BRIGHTEN study. Diabetol Int 6: 8-18
12. Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, et al. (2016) Efficacy and safety of iparagliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials. J Diabetes Investig 7: 544-554.
13. Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, et al. (2016) Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 63: 589-596.
14. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, et al. (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33.
15. Rückert IM, Heier M, Rathmann W, Baumeister SE, Döring A, et al. (2011) Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. PLoS One 6: e22932.
16. Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838.
17. Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, et al. (2016) Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology 157: 1029-1042.
18. Henly DC, Phillips JW, Berry MN (1995) Stimulation of gluconeogenesis leads to an increased rate of beta-oxi-dation in hepatocytes from fasted diabetic but not from fasted normal rats. Biochim Biophys Acta 1244: 92-98.
19. Kahl S, Strassburger K, Nowotny B, Livingstone R, Kluppelholz B, et al. (2014) Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 9: e94059.
20. Bozkurt L, Göbl CS, Tura A, Chmelik M, Prikoszovich T, et al. (2012) Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One 7: e32710.